AbbVie's venetoclax made available on UK's early access scheme for CLL

US drugmaker AbbVie (NYSE: ABBV) has received a positive scientific opinion through the UK’s Early Access to Medicines Scheme (EAMS) for venetoclax, a treatment for chronic lymphocytic leukemia (CLL).

Venetoclax, which was granted this status from the Medicines and Healthcare products Regulatory Agency, is now potentially available to patients with certain types of difficult-to-treat CLL while the marketing authorization application is under review by the European Medicines Agency.

An investigational therapy with trials in relapsed or refractory CLL, an area of high unmet need, venetoclax is AbbVie’s first oncology therapy in the UK and the first treatment for CLL to be made available through EAMS.